Rivastigmine in alzheimer's disease and Parkinson's disease dementia: An ADAS-Cog factor analysis

American Journal of Alzheimer's Disease and other Dementias

Volumn 26, Issue 6, 2011, Pages 443-449

  Weintraub, Daniel ^a   Somogyi, Monique ^b   Meng, Xiangyi ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

ADAS cog; Alzheimer's disease; factor analysis; Parkinson's disease dementia; rivastigmine

Indexed keywords

RIVASTIGMINE;

ADULT; ALZHEIMER DISEASE; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DEMENTIA; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; FACTORIAL ANALYSIS; FEMALE; HUMAN; LANGUAGE; MAJOR CLINICAL STUDY; MEMORY; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY;

EID: 84555187597     PISSN: 15333175     EISSN: 19382731     Source Type: Journal    
DOI: 10.1177/1533317511424892     Document Type: Article

References (14)

1. Emre M, Cummings JL, Lane RM. Rivastigmine in dementia associated with Parkinson's disease and Alzheimer's disease: similarities and differences. J Alzheimers Dis. 2007 ; 11 (4). 509-519 (Pubitemid 47094023)
2. Winblad B, Cummings J, Andreasen N, et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease-rivastigmine patch versus capsule. Int J Geriatr Psychiatry. 2007 ; 22 (5). 456-467 (Pubitemid 46831690)
3. Rösler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ. 1999 ; 318 (7184). 633-638
4. Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol. 1998 ; 1 (2). 55-65 (Pubitemid 28323228)
5. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med. 2004 ; 351 (24). 2509-2518 (Pubitemid 39603164)
6. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984 ; 141 (11). 1356-1364
7. Weyer G, Erzigkeit H, Kanowski S, Ihl R, Hadler D. Alzheimer's disease assessment scale: reliability and validity in a multicenter clinical trial. Int Psychogeriatr. 1997 ; 9 (2). 123-138 (Pubitemid 27455497)
8. Harvey PD, Ferris SH, Cummings JL, et al. Evaluation of dementia rating scales in Parkinson's disease dementia. Am J Alzheimers Dis Other Demen. 2010 ; 25 (2). 142-148
9. Olin J, Schneider L. Assessing response to tacrine using the factor analytic structure of the Alzheimer's Disease Assessment Scale (ADAS)-cognitive subscale. Int J Geriatr Psychiatry. 1995 ; 10 (9). 753-756
10. Grossberg GT, Schmitt FA, Meng X, Tekin S, Olin JT. Effects of transdermal rivastigmine on ADAS-cog items in mild-to-moderate Alzheimer's disease. Am J Alzheimers Dis Other Demen. 2010 ; 25 (8). 627-633
11. Schneider LS, Anand R, Farlow MR. Systematic review of the efficacy of rivastigmine for patients with Alzheimer's disease. Int J Geriatr Psychopharmacol. 1998 ; 1 (suppl 1). S26 - S34
12. Feldman HH, Lane R. Rivastigmine: A placebo-controlled trial of BID and TID regimens in patients with Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2007 ; 78 (10). 1056-1063
13. Farlow MR, Cummings JL, Olin JT, Meng X. Effects of oral rivastigmine on cognitive domains in mild-to-moderate Alzheimer's disease. Am J Alzheimers Dis Other Demen. 2010 ; 25 (4). 347-352
14. Schmitt FA, Aarsland D, Bronnick KS, Meng X, Tekin S, Olin JT. Evaluating rivastigmine in mild-to-moderate Parkinson's disease dementia using ADAS-cog items. Am J Alzheimers Dis Other Demen. 2010 ; 25 (5). 407-413